Cell and Gene Therapy Business Outlook: Volume 1, Issue 14
10 Jan 2022
Categories:
Cell and Gene Therapy Business Outlook
Don't miss our new twice-monthly publication dedicated to cell and gene therapy. Cell and Gene Therapy Business Outlook offers the following:
- Market Sizing and Forecasting of CAGT Markets
- Executive News Summaries
- Deals Between CAGT Companies Tracked
- Financing
- Trends in the Industry
- Important Science That Will Shape Tomorrow’s Business
- Company Profiling and Quarterly Results Summaries
- Updates on Pipelines and Important Clinical Trials
- Cell and Gene Therapy Tools
- Cell and Gene Therapy CMOs
- And More
Table of Contents
- Untitled Chapter
-
Market Analysis
-
Focus on Cell and Gene Therapy for Liver Diseases
- Overview of Cell and Gene Therapy for Liver Diseases
- Market Outlook
- Products in Development
- Regional Analysis
-
Top Company Briefs
- Alnylam Pharmaceuticals
- Bristol-Myers Squibb
- Arrowhead Pharmaceuticals
- Steminent Biotherapeutics
-
Focus on Cell and Gene Therapy for Liver Diseases
-
Executive News Brief
- Recent developments in cell and gene therapy
-
Recent Funding Deals
- 2022 Starts with Two Hundred-Million Dollar Deals
-
Cell and Gene Therapy Market News and News Analysis
- SalioGen Therapeutics Raises $115 Million for Gene Coding Platform
- Synthetic Biology Company Senti Bio to Go Public with SPAC Merger
-
Cell and Gene Therapy Expert Interviews
- INTERVIEW: Amanda Cashin, Illumina for Startups
- Recent CGT Deal Activity